3′-Phosphoadenosine 5′-phosphosulfate synthase 1 (PAPSS1) knockdown sensitizes non-small cell lung cancer cells to DNA damaging agents

Standard treatment for advanced non-small cell lung cancer (NSCLC) with no known driver mutation is platinum-based chemotherapy, which has a response rate of only 30–33%. Through an siRNA screen, 3′-phosphoadenosine 5′-phosphosulfate (PAPS) synthase 1 (PAPSS1), an enzyme that synthesizes the biologi...

Descripción completa

Detalles Bibliográficos
Autores principales: Leung, Ada W. Y., Dragowska, Wieslawa H., Ricaurte, Daniel, Kwok, Brian, Mathew, Veena, Roosendaal, Jeroen, Ahluwalia, Amith, Warburton, Corinna, Laskin, Janessa J., Stirling, Peter C., Qadir, Mohammed A., Bally, Marcel B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4627299/
https://www.ncbi.nlm.nih.gov/pubmed/26220590

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4627299/
https://www.ncbi.nlm.nih.gov/pubmed/26220590

Ejemplares similares